Celldex Therapeutics
- Biotech or pharma, therapeutic R&D
Celldex Therapeutics is a clinical stage biotechnology company that is leading the science at the intersection of mast cell biology and the development of transformative antibody therapeutics.
Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease.
Address
HamptonNew Jersey
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}